Ember LifeSciences Expands Series A to $27M Led by TDF Ventures

The new funding brings Ember LifeSciences’s Series A total to $27 million, following an earlier round led by Sea Court Capital.

The company plans to use the funds to grow its operations and continue developing its products and services.

This comes as Ember LifeSciences announces the full commercial availability of the Ember Cube 2, an award-winning reusable and modular solution designed to improve cold chain logistics through real-time monitoring and cloud-based tracking.

The pharmaceutical cold chain loses billions of dollars each year due to temperature issues, and the industry is under increasing pressure as more medicines and vaccines require temperature-controlled shipping.

Ember LifeSciences is working to solve this problem with its reusable shipping platform. Its Ember Cube 2 was recently recognized as “Best of the Best” by the Red Dot Award for product design.

Read More:Fields Good Raises $1.8M in Pre-Seed Funding

"Investments from Amgen and TDF Ventures provide us with the deep industry insights needed to scale our logistics platform rapidly," said Clay Alexander, founder and CEO of Ember LifeSciences. "Their investments mark a turning point as we expand our global footprint and bring a new level of precision to healthcare delivery."

About Ember LifeSciences

Founded by Clay Alexander, Ember LifeSciences was launched as an offshoot of Ember Technologies, the design-led temperature control company known for its award-winning temperature control mug, which has generated over half a billion dollars in sales. Ember LifeSciences aims to transform global medicine distribution by using Ember’s proprietary temperature control technology to improve the transportation of life-saving medicines and vaccines worldwide.

Read More:Patron Points Receives Investment From Straylight Capital